Eprenetapopt + azacitidine Siv Tau Zoo! --- 1/2 ib

Aprea Therapeutics tsis ntev los no tshaj tawm cov txiaj ntsig zoo ntawm theem 2 kev sim tshuaj kho mob uas tau tshuaj xyuas eprenetapopt (APR-246) ua ke nrog azacitidine (AZA) rau TP53 hloov pauv myelodysplastic syndrome (MDS) thiab mob myelodysplastic syndromes. Kev ua tau zoo thiab nyab xeeb ntawm kev kho txij nkawm tom qab hloov pauv rau cov neeg mob nrog AML.

eprenetapopt yog cov tshuaj me me uas tau ua pov thawj los kho qhov hloov pauv thiab tsis ua haujlwm p53 cov protein rau kev hloov pauv thiab ua haujlwm ntawm cov tsiaj qus hom p53, rov ua dua nws, thiab ua kom muaj cov phiaj xwm kev tuag hauv tib neeg cov qog nqaij hlav cancer.

Ntawm 33 tus neeg mob rau npe rau hauv qhov kev sim, qhov 1-xyoo tsis muaj kev rov muaj sia nyob (RFS) tus nqi tom qab hloov pauv yog 58%, thiab lub sijhawm RFS nruab nrab yog 12.1 hli. Qhov 1-xyoos tag nrho kev muaj sia nyob (OS) tus nqi tom qab hloov pauv yog 79%, thiab lub sijhawm nruab nrab OS yog 19.3 hli. Ib tus lej ntawm cov kev sim tshuaj yav dhau los los tshuaj xyuas qhov tshwm sim ntawm TP53 hloov pauv MDS thiab AML cov neeg mob tom qab hloov pauv tau tshaj tawm tias 1-xyoo RFS tus nqi tom qab hloov pauv yog kwv yees li 30%, thiab lub sijhawm nruab nrab OS yog kwv yees li 5-8 lub hlis. Hauv qhov kev sim no, cov neeg mob tau zam txoj cai tom qab hloov pauv ntawm prerenepopt thiab azacitidine.

Aprea npaj los tham txog cov ntaub ntawv ntawm theem 2 kev kuaj mob no nrog Asmeskas FDA nyob rau ib nrab ntawm 2021, thiab cia siab tias yuav tshaj tawm cov ntaub ntawv ntawm kev sib tham tshawb fawb yav tom ntej lossis kev kho mob. Asmita Mishra, kws tshawb fawb ntawm H Lee Moffitt Cancer Center thiab Research Institute hauv Tebchaws Meskas, tau hais tias:" RFS thiab OS cov ntaub ntawv ntawm eprenetapopt thiab azacitidine rau kev kho txij nkawm ntawm cov neeg mob TP53 hloov chaw MDS thiab AML tom qab hloov chaw yog qhov zoo siab heev. Txawm hais tias kev hloov pauv tam sim no tsuas yog muaj peev xwm kho tau rau cov neeg mob nrog TP53 hloov chaw MDS thiab AML, tab sis raws li tus txheej txheem kev kho mob tam sim no, kev pheej hmoo ntawm kev rov tshwm sim tseem muaj ntau, thiab qhov nruab nrab OS tom qab hloov pauv tau txwv heev, tsuas yog 8 lub hlis lossis tsawg dua. Yog tias tau txais Kev Pom Zoo ntawm kev siv eprenetapopt thiab azacitidine rau kev kho tom qab hloov pauv kho tuaj yeem sawv cev rau cov txheej txheem kho tshiab uas tuaj yeem muaj txiaj ntsig txhim kho cov txiaj ntsig ntawm cov neeg mob nrog kev xaiv kho mob tsawg."

APR-426 qauv qauv (cov duab los ntawm: selleck.cn)

MDS yog cov qog ua qog ntawm cov qia hematopoietic. Cov pob txha pob txha tsis tuaj yeem tsim cov qe ntshav txaus. Kwv yees li 30-40% ntawm cov neeg mob MDS yuav nce mus rau mob myeloid leukemia (AML), thiab kev hloov pauv hauv p53 qog nqaij hlav suppressor protein tau xav ncaj qha mus rau kev txhim kho kab mob. p53 kev hloov pauv tam sim no txog li 20% ntawm MDS thiab AML cov neeg mob thiab cuam tshuam nrog kev kwv yees tsis zoo tag nrho. Tam sim no, tsis muaj kev pom zoo kho tshwj xeeb rau TP53 hloov pauv MDS lossis AML cov neeg mob.